Oral BPC-157 increased honeybee colony strength and reduced Nosema ceranae parasite load
Background
The microsporidian parasite Nosema ceranae is a significant threat to honeybee populations worldwide, causing a disease known as nosemosis. This infection leads to severe gut epithelial cell degeneration, immune suppression, and a reduced lifespan for individual bees. On a larger scale, it can culminate in sudden and catastrophic colony collapse, posing a major problem for apiculture and agriculture that relies on pollination. Current therapeutic options are limited or face challenges, creating a need for novel, effective treatments. The stable gastric pentadecapeptide BPC-157 is known for its cytoprotective and gut-healing properties in other models, making it a promising candidate to counteract the gut damage central to Nosema ceranae pathogenesis and support colony health.
Study Design
This field trial investigated the therapeutic potential of BPC-157 in honeybee colonies naturally infected with Nosema ceranae. The treatment group received 0.25 L of sugar syrup supplemented with 0.1 µg/ml BPC-157 daily for 21 consecutive days. The control group received an equal volume of pure sugar syrup. Dosing was administered via feeders placed under the hive roofs at the end of the beekeeping season. Primary endpoints were the strength of the honeybee colonies (estimated number of bees) and the N. ceranae spore load in adult honeybees, assessed on Days 1, 20, and 30 post-initiation. Histological analysis of the midgut wall was also performed to assess cellular damage.
Results
BPC-157 administration led to a significant increase in honeybee colony strength. The estimated number of honeybees in the treated colonies grew from 36,100 ± 698 on Day 1 to 64,860 ± 468 on Day 20, before stabilizing at 53,214 ± 312 on Day 30. Concurrently, the parasite burden decreased substantially in the BPC-157 group. The average N. ceranae spore load per bee dropped progressively from 6.286 ± 2.336 million on Day 1 to 3.753 ± 1.835 million on Day 20, and further to 2.005 ± 1.534 million by Day 30.
Histological examination revealed that while control bees showed severe damage to midgut wall layers and epithelial cells, these damages were markedly attenuated in bees that received BPC-157, with particular preservation of the outer muscular coat.
This demonstrates that oral BPC-157 supplementation not only controlled the parasitic infection but also protected against the associated gut pathology under real-world apiary conditions.
Key Findings
- BPC-157 treatment increased honeybee colony strength from an estimated 36,100 bees at baseline to 64,860 bees on Day 20.
- The parasite load of N. ceranae in treated bees decreased from 6.286 million spores/bee on Day 1 to 2.005 million spores/bee on Day 30.
- BPC-157 supplementation (0.1 µg/ml in sugar syrup) was administered orally for 21 consecutive days.
- Histological analysis showed BPC-157 markedly attenuated the severe midgut wall and epithelial cell damage caused by N. ceranae infection.
Why It Matters
This study presents BPC-157 as a viable therapeutic agent for combating Nosema ceranae, a major driver of honeybee colony collapse. For beekeepers, this suggests a novel, easily administered oral treatment that could significantly improve colony health, strength, and survival, especially at the critical end-of-season period. The findings highlight the peptide's potent gut-protective and restorative effects, extending its known benefits to an invertebrate model and against a parasitic infection. The results support a protocol of supplementing feed with BPC-157 as a direct intervention for diseased colonies. While promising, this is the first field trial of its kind, and further research would be needed to optimize dosing, understand long-term effects, and determine its efficacy across different environmental conditions before it could be considered a standard apiary practice.
TitrateLab articles covering BPC-157
Written by TitrateLab, separately from the study summarized above.
bpc-157
nosema ceranae
honeybee
gut health
parasitic infection
animal study
